Partnering to develop IBD treatment

Israel’s Teva is partnering with France’s Sanofi (see also here) to develop and commercialize TEV 574, currently in Phase 2b clinical trials, for the anti-TL1A treatment of ulcerative colitis and Crohn’s Disease, two types of inflammatory bowel disease (IBD).

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *